German China
Search

Ireland: Metabolic Diseases Treatment of Fatty Liver Disease: Fitness More Important than Weight Loss

| Editor: Alexander Stark

A new Trinity study highlights that fitness may be a more important clinical endpoint for improvement in patients with fatty liver disease during exercise trials, rather than weight loss. The findings have been published in the medical journal Alimentary Pharmacology and Therapeutics.

A new study highlights that increased fitness may be a more important clinical endpoint for patients with fatty liver disease, rather than weight loss.
A new study highlights that increased fitness may be a more important clinical endpoint for patients with fatty liver disease, rather than weight loss.
(Source: Public Domain / Pixabay )

Dublin/Ireland — Metabolic associated fatty liver disease (MAFLD) is a condition characterised by a build-up of fat in the liver. The liver is central to a suite of vital processes in the body including digestion, blood clotting and energy production.

If left untreated MAFLD can lead to serious complications such as liver fibrosis (scarring), cirrhosis, liver failure and liver cancer, as well as cardiovascular and metabolic issues. Risk factors for developing MAFLD include type 2 diabetes and obesity. The global estimated prevalence of MAFLD is 25 %, making it the leading cause of chronic liver disease worldwide, and is quickly becoming the leading cause of cirrhosis and liver cancer in liver transplant candidates in the western world.

Up to now, due to the lack of approved pharmacological interventions, treatment has been a combination of prescribed weight loss and physical activity, with a weight loss target of 7-10 % being the primary treatment endpoint. There is some evidence that exercise training alone without significant weight loss can reduce liver fat content (assessed using non-invasive methodologies such as transient elastography and ultrasound) in MAFLD patients. However, the independent effects of exercise alone on biopsy-measured outcomes (the gold standard for diagnosing and assessing MAFLD) have been unknown.

This new study highlights that increased fitness, the result of aerobic exercise participation, may be a more important clinical endpoint for improvement in MAFLD patients during exercise trials, rather than weight loss.

In Ireland and worldwide, MAFLD is a silent epidemic. In Ireland, there is currently no national screening programme for the disease, so the true prevalence in Ireland is unknown. However, St James’s Hospital, Dublin, where the study took place, now has over 1000 patients on their own database, with the numbers growing year on year.

The Trinity study is the first to demonstrate significant improvements in biopsy-measured liver outcomes in a MAFLD cohort following an exercise-only intervention, without clinically significant weight loss. The study also demonstrates that improvements in biopsy-measured liver outcomes were significantly related to improvements in fitness levels. The study also found however, that when patients were followed up longitudinally, none of the benefits of the exercise intervention were sustained.

The research is unique in that the team used repeat biopsies in MAFLD patients during an exercise-only intervention. Only two previous studies have been conducted using repeat biopsies in exercise-only trials, but these studies had significant methodological limitations. These studies used low-intensity resistance exercise and lacked exercise supervision, which may have led to non-significant changes on liver biopsy outcomes. The Trinity study is also the first to relate improvements on liver biopsies with improvements in fitness, suggesting a potential interrelationship between the two outcomes.

The paper is published in the journal Alimentary Pharmacology and Therapeutics

(ID:46749549)